Angela Osborne

Founder & Board Director, eXmoor Pharma

Angela Osborne is Founder and Board Director of eXmoor Pharma, a UK cell and gene therapy partner supporting developers from strategy through process development, GMP manufacturing and commercialisation. A biochemical engineer with a BSc Eng and PhD from University College London, Angela founded eXmoor in 2004 and has helped grow it from specialist consultancy to integrated CDMO. With more than 30 years’ experience in biopharmaceutical and advanced therapy businesses, facilities and processes, she works with clients to align technical requirements with strategic goals and meaningful patient impact. Driven by a passion for bringing life-changing therapies to patients, Angela is also co-founder of the amc (ATMP Manufacturing Community), supporting best practice across the sector. She is valued for technical depth, commercial perspective and collaborative problem-solving. Away from work, Angela enjoys the southwest coast path, campervanning, gardening on her Exmoor farm, sailing the south Devon coast and horse riding.

Cath Green

Head of Clinical BioManufacturing Facility, University of Oxford

Catherine Green is Professor of Clinical Biomanufacturing at the University of Oxford. She also heads the Nuffield Department of Medicine’s Clinical Biomanufacturing Facility and is a Fellow at Exeter College, Oxford.

Professor Green’s passion for science was solidified during her years spent studying biochemistry as an undergraduate at the University of Cambridge. She went on to receive an Imperial Cancer Research Fund (now Cancer Research UK) scholarship to complete her PhD research in the genetics of yeast DNA damage responses. Prior to joining the University of Oxford in 2012, Green held several prestigious fellowships, including a Marie Curie Fellowship at the Institut Curie in Paris, and a Cancer Research UK Research Fellowship in the Department of Zoology at the University of Cambridge, investigating the repair and replication of DNA damage in human cells.

Currently, Professor Green specialises in creating IMPs for clinical trials. She and her team at the Clinical Biomanufacturing Facility have developed several novel vaccines for first-in-human trials, targeting diseases such as Ebola virus, Zika virus, Middle East respiratory syndrome, plague, gonorrhoea, and rabies, amongst others. The CBF aims to provide the link between academic research and clinical drug development, to allow all our collaborators to make rapid progress into clinical trials.

In 2021, Green was awarded an OBE for her services to science and public health following her significant contribution as manufacturing lead in the development of the Oxford AstraZeneca COVID-19 vaccine.